Q2 EPS Estimates for Legend Biotech Increased by Analyst

Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) – Investment analysts at HC Wainwright lifted their Q2 2026 earnings per share (EPS) estimates for Legend Biotech in a research note issued on Wednesday, July 15th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings per share of $0.22 for the quarter, up from their prior forecast of $0.18. HC Wainwright has a “Buy” rating and a $65.00 price target on the stock. The consensus estimate for Legend Biotech’s current full-year earnings is ($0.01) per share. HC Wainwright also issued estimates for Legend Biotech’s Q3 2026 earnings at $0.16 EPS.

Several other equities analysts also recently commented on the stock. TD Cowen upped their price target on shares of Legend Biotech to $29.00 and gave the company a “hold” rating in a report on Wednesday, May 13th. Weiss Ratings downgraded shares of Legend Biotech from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, July 10th. JPMorgan Chase & Co. started coverage on Legend Biotech in a research report on Monday. They set a “neutral” rating and a $35.00 target price for the company. Morgan Stanley cut their target price on Legend Biotech from $49.00 to $48.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 13th. Finally, UBS Group increased their price target on Legend Biotech from $31.00 to $49.00 and gave the stock a “buy” rating in a report on Wednesday, June 3rd. Ten research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Legend Biotech has a consensus rating of “Moderate Buy” and a consensus price target of $57.00.

Legend Biotech Trading Down 10.2%

Legend Biotech stock opened at $23.04 on Thursday. The firm has a 50-day moving average price of $29.56 and a 200-day moving average price of $23.33. The firm has a market capitalization of $4.28 billion, a PE ratio of -33.88 and a beta of 0.34. Legend Biotech has a 12-month low of $16.24 and a 12-month high of $45.30.

Legend Biotech (NASDAQ:LEGN) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.03) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.01). Legend Biotech had a negative net margin of 21.98% and a negative return on equity of 24.92%. The firm had revenue of $305.10 million for the quarter, compared to the consensus estimate of $306.51 million. During the same quarter last year, the firm earned ($0.07) EPS. The company’s revenue was up 56.5% on a year-over-year basis.

Hedge Funds Weigh In On Legend Biotech

A number of institutional investors have recently modified their holdings of the stock. The Manufacturers Life Insurance Company raised its position in Legend Biotech by 5.8% during the 1st quarter. The Manufacturers Life Insurance Company now owns 10,393 shares of the company’s stock valued at $188,000 after purchasing an additional 570 shares in the last quarter. Invesco Ltd. grew its position in shares of Legend Biotech by 4.4% during the 4th quarter. Invesco Ltd. now owns 13,710 shares of the company’s stock worth $298,000 after buying an additional 581 shares in the last quarter. Resona Asset Management Co. Ltd. grew its position in shares of Legend Biotech by 3.1% during the 1st quarter. Resona Asset Management Co. Ltd. now owns 20,386 shares of the company’s stock worth $366,000 after buying an additional 607 shares in the last quarter. Parallel Advisors LLC increased its stake in shares of Legend Biotech by 171.9% during the third quarter. Parallel Advisors LLC now owns 1,047 shares of the company’s stock valued at $34,000 after buying an additional 662 shares during the period. Finally, Fox Run Management L.L.C. increased its stake in shares of Legend Biotech by 4.3% during the fourth quarter. Fox Run Management L.L.C. now owns 20,806 shares of the company’s stock valued at $452,000 after buying an additional 863 shares during the period. 70.89% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CEO Ying Huang sold 5,566 shares of Legend Biotech stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $14.78, for a total transaction of $82,265.48. Following the completion of the sale, the chief executive officer owned 241,872 shares in the company, valued at $3,574,868.16. This trade represents a 2.25% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.02% of the stock is owned by corporate insiders.

About Legend Biotech

Legend Biotech (NASDAQ: LEGN) is a commercial-stage biopharmaceutical company specializing in the development and commercialization of chimeric antigen receptor T-cell (CAR-T) therapies for oncology. Headquartered in Somerset, New Jersey, with research and development operations in Shanghai, the company leverages a global infrastructure to advance innovative cellular therapies. Legend Biotech pursues a strategy of strategic collaboration to extend its reach, most notably through its partnership with Janssen Biotech, a subsidiary of Johnson & Johnson.

The company’s lead asset, ciltacabtagene autoleucel (commercially marketed as Carvykti), is a B-cell maturation antigen (BCMA)–directed CAR-T therapy for the treatment of relapsed or refractory multiple myeloma.